Prognosis and stage shift of patients with cancer detected on multimodal cancer screening including FDG-PET

1611 Objectives: "PET cancer screening", in other words, multimodal cancer screening including whole body FDG-PET, becomes performed widely in Japan, but prognosis and survival rate of cancer screening examinees are not yet evaluated, and utility of "PET cancer screening" is not yet established. In this study, we evaluate the prognosis of cancer cases detected by PET cancer screening, and evaluate the utility of PET cancer screening. Methods: 16,923 healthy individuals without cancer history who underwent PET cancer screening were enrolled. We classified these examinees into following 2 groups; (I) First time PET cancer screening examinees (Baseline Screening Group: BSG) (II) Second or latter PET cancer screening examinees and not detected cancer in first time screening (Repeater Group: RG) 3234 individuals of RG underwent repeated screening with 6-47 months intervals. 248 cases (of 16923, 1.47%) of BSG and 42 cases (of 3234, 1.30%) of RG was diagnosed cancer. Between these two groups, significant differences were not seen in profiles of cancer types. We investigated pathological stage and prognosis of these cancer patients, and evaluate disease-free survival rate and survival interval, and compare these 2 groups. (Median follow up interval is 15.1 months) Results: 49.3% (113 of 248 cases) of BSG cancer cases, and 76.2% (32 of 42 cases) of RG cancer cases, were detected during clinical stage 0 or I (p Research Support (if any): This work was supported by grants-in-aid for Cancer Research for the Third-Term Comprehensive 10-Year Strategy for Cancer Control and for Research on Advanced Medical Technology from the Ministry of Health, Labor and Welfare of Japan.